Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats

Yoshitaka Iwanaga ¹, Masahiko Hoshijima , Yusu Gu

⁰Department of Medicine, University of California, San Diego, La Jolla, California 92093-0613B, USA.

The Journal of Clinical Investigation +

|

March 3, 2004

View abstract on PubMed

Summary

Phospholamban (PLN) inhibition using S16EPLN gene therapy improved heart function in rats with heart failure after myocardial infarction. This approach offers a potential chronic treatment for acquired heart failure.

Area Of Science

Cardiology
Molecular Biology
Gene Therapy

Background

Phospholamban (PLN) inhibition shows promise in genetic cardiomyopathies.
Previous studies demonstrated S16EPLN's efficacy in preventing heart failure in hamsters.

Purpose Of The Study

To investigate the effects of PLN inhibition on acquired heart failure in a rat model post-myocardial infarction (MI).
To evaluate the chronic therapeutic potential of S16EPLN delivered via recombinant adeno-associated virus (rAAV) gene transfer.

Main Methods

Rats with established heart failure post-MI received transcoronary gene transfer of S16EPLN or saline control.
Left ventricular function, dimensions, hemodynamics, cardiac mass, myocyte size, and fibrosis were assessed at 2 and 6 months post-gene transfer.

Main Results

S16EPLN treatment led to increased left ventricular ejection fraction and attenuated LV dilation compared to controls.
Hemodynamic improvements included lower LV end-diastolic pressures and enhanced cardiac contractility and relaxation.
MI-S16EPLN rats exhibited reduced LV mass, myocyte size, and cardiac fibrosis.

Conclusions

In vivo PLN inhibition via rAAV gene transfer is an effective chronic treatment strategy for heart failure following myocardial infarction.
This approach demonstrates significant potential for managing acquired heart failure conditions.

Related Concept Videos